Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaap Verweij

Showing results (11-20 of 234) with videos related to

Pageof 24
Sort By:
Cancer Chemotherapy and Biological Response Modifiers|April 22, 2003
SarcomasJaap Verweij
Current Opinion in Oncology|February 21, 2012
Clinical trials in drug development: a minimalistic approachJaap Verweij
Cancer Treatment and Research|June 26, 2004
KIT and PDGF as targetsJaap Verweij
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Soft tissue sarcoma trials: one size no longer fits allJaap Verweij
The Oncologist|June 17, 2008
Other endpoints in screening studies for soft tissue sarcomasJaap Verweij
Nature Reviews. Clinical Oncology|May 11, 2016
Health policy: Affordability of drugs used in oncology health careStefan Sleijfer, Jaap Verweij
Cancer Treatment and Research|June 26, 2004
Targeted therapy: ready for prime time?Caroline Seynaeve, Jaap Verweij
Onkologie|February 13, 2008
Trial methodology in soft tissue sarcomas; the 'one plus one is three or zero' phenomenonStefan Sleijfer, Jaap Verweij
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Paclitaxel pharmacokinetics, threshold models, and dosing strategiesAlex Sparreboom, Jaap Verweij
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2009
Phase I drug combination trial design: walking the tightropePaul Hamberg, Jaap Verweij
Pageof 24

Showing results (11-20 of 234) with videos related to

Sort By:
Pageof 24
Cancer Chemotherapy and Biological Response Modifiers|April 22, 2003
SarcomasJaap Verweij
Current Opinion in Oncology|February 21, 2012
Clinical trials in drug development: a minimalistic approachJaap Verweij
Cancer Treatment and Research|June 26, 2004
KIT and PDGF as targetsJaap Verweij
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Soft tissue sarcoma trials: one size no longer fits allJaap Verweij
The Oncologist|June 17, 2008
Other endpoints in screening studies for soft tissue sarcomasJaap Verweij
Nature Reviews. Clinical Oncology|May 11, 2016
Health policy: Affordability of drugs used in oncology health careStefan Sleijfer, Jaap Verweij
Cancer Treatment and Research|June 26, 2004
Targeted therapy: ready for prime time?Caroline Seynaeve, Jaap Verweij
Onkologie|February 13, 2008
Trial methodology in soft tissue sarcomas; the 'one plus one is three or zero' phenomenonStefan Sleijfer, Jaap Verweij
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Paclitaxel pharmacokinetics, threshold models, and dosing strategiesAlex Sparreboom, Jaap Verweij
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2009
Phase I drug combination trial design: walking the tightropePaul Hamberg, Jaap Verweij
Pageof 24